Clinical Trials Logo

Second-degree Burn clinical trials

View clinical trials related to Second-degree Burn.

Filter by:
  • None
  • Page 1

NCT ID: NCT04684121 Withdrawn - Thermal Burn Clinical Trials

Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of Granexin® gel to promote accelerated healing of second-degree (deep partial thickness) thermal burns.

NCT ID: NCT04149808 Withdrawn - Second-degree Burn Clinical Trials

Mepilex Ag vs. Xeroform in Pediatric Patients That Sustain Partial Thickness Burn Injury

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

Pediatric patients that sustain partial thickness burn injuries to their extremities require regular scheduled dressings and weekly appointments for better healing. Typically, the dressing used at Children's Hospital of Michigan is Xeroform, which can often be painful when changing at the weekly clinic appointment. Mepilex Ag is also an approved treatment for these types of burns and has the potential to cause less pain with dressing changes, however is not used as frequently due to a much higher cost. Studies evaluating the treatment of partial thickness burns in pediatric patients have shown decreased cost and length of stay associated with dressings that are silver impregnated, like Mepilex Ag. However, these studies are all retrospective with a possible selection bias to patients. In addition, several studies have suggested less pain with newer foam and hydrofiber dressings. We are conducting a prospective study using patients with partial thickness burns of their extremities, applying Xeroform on half of the burn, and Mepilex Ag on the other half of the burn, to remove confounding variables between patients to determine the optimal burn dressing for partial thickness scald burns for pediatric patients. A partial thickness burn, also known as a second degree burn, extends into the top two layers of the skin, not passing the hypodermis. Our goal is to determine if Xeroform or Mepilex Ag is superior treatment for partial thickness burns in pediatric patients for healing time, appearance of scar, and patient pain and comfort during treatment and dressing changes.

NCT ID: NCT03530150 Completed - Second-degree Burn Clinical Trials

Pirfenidone and Its Role in Burn Wound Healing

Start date: January 1, 2017
Phase: Phase 2
Study type: Interventional

Burn patients which skin has been lost a rapid growth of the skin is a foremost in their treatment. Due to the injury, burn patients undergo a systemic inflammation that helps the skin heal faster. However, several studies have shown that this inflammation increases the levels of several inflammatory molecules that impairs skin growing, which further delays the recovery of burn patients. As such, by inhibiting these inflammatory molecules with the administration of a medication called pirfenidone burn patients might present faster rates of skin growth and recovery. Thus, patients suffering from a burn injury will be recruited at the emergency department of the Hospital University in Monterrey Mexico. Afterward, patients will be randomized to either receive pirfenidone 600 mg orally once per day or usual care consisting of covering the wound with hydrocolloid dressings. To assess the amount of newly growth skin investigators will take a small piece of the skin to further evaluate it through a microscope.

NCT ID: NCT03048188 Recruiting - Second-degree Burn Clinical Trials

Manuka Honey in Second- and Grafted Third-degree Burns

Start date: July 15, 2015
Phase: N/A
Study type: Interventional

Treatment strategies of II. degree burn wounds and split-skin grafted III. degree burn wounds aim at reducing infection and improving reepithelialization. The aim of this study is to evaluate time to reepithelialization, pain, microbiology and handling of manuka honey dressings with second-degree burn wounds and split-skin grafted burn wounds.

NCT ID: NCT02108535 Completed - Second-degree Burn Clinical Trials

Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns

ARGENTUM
Start date: November 2013
Phase: Phase 4
Study type: Interventional

The evidence is insufficient to determine whether the types of dressings containing silver differ in time / proportion for complete wound healing and pain. We will analyze the cost-effectiveness of these dressings in outpatients, considering the service provided by the Brazilian National Public Health System.

NCT ID: NCT01055587 Completed - Second Degree Burn Clinical Trials

Diagnostic of Infections Following Major Abdominal Surgery and Burn Injury

Earlygnost
Start date: September 2009
Phase: N/A
Study type: Observational

This study was designed to investigate, if new biomarkers may improve the early diagnostic of infections following major abdominal surgery and severe burn injuries.

NCT ID: NCT00742183 Completed - Second Degree Burn Clinical Trials

Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®

Start date: August 2008
Phase: N/A
Study type: Interventional

The primary objective is to compare the incremental costs (direct and indirect) and benefits (healing outcomes, quality of life) of using foam silver dressing (Mepilex® Ag) to a Silver sulfadiazine 1% cream (Silvadene®) from the perspective of the health care provider. The secondary objectives are to investigate the safety, the tolerance and the performance on burn status including pain.